Acadia Pharmaceuticals Inc. (ACAD) Stock: Price, Forecast & Analyst Target
Acadia Pharmaceuticals Inc. (ACAD) — MoonshotScore 68/100 (Strong band), calculated Nov 18, 2026. Price $17.83 (-2.67%), as of the Nov 18, 2026 trading session; market cap $3.08B.
Educational signal · not a buy or sell recommendation · How to read this
Acadia Pharmaceuticals Inc. · ACAD · NASDAQ · Healthcare · Biotechnology
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Acadia Pharmaceuticals (ACAD)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a strong balance sheet and durable growth, with no real weak spot — fairly priced, so not a bargain entry. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Sound; Valuation: Fair; Growth Durability: Growing; Momentum: Quiet.
- quarterly revenue $342M (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 7 of the last 8 reports
- Altman Z 4.88 · Piotroski F 4
Helping: business quality, balance-sheet strength, durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 68 | Strong | |
| 69 | Strong | |
| 68 | Strong | |
| 68 | Strong | |
| 68 | Strong | |
| 68 | Strong |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $17.83 | |
| Change on the day | -2.67% | |
| 52-week range | $15.86–$30.96 | |
| Market capitalisation | $3.08B | — |
| Price / earnings (trailing) | 8.60 | |
| Shares traded on the day | 1.89M | |
| Beta (volatility vs the S&P 500) | 0.89 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Acadia Pharmaceuticals (ACAD): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Acadia Pharmaceuticals (ACAD), and what does it report?
Short answer
Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Acadia Pharmaceuticals Inc. (ACAD) is listed on NASDAQ. Acadia Pharmaceuticals Inc. (ACAD) is classified as Healthcare / Biotechnology. SEC filing business address: 12830 EL Camino Real, Suite 400, SAN Diego, CA, 92130. It employs 797 people and is led by Catherine E. Owen Adams. In Q3 FY2026 it reported revenue of $342M and net income of $54M. The market values it at $3.08B.
What do the latest results show for Acadia Pharmaceuticals (ACAD)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $342M. Against analyst estimates the company has EPS beat 7 of the last 8 reports.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $342M | $54M | $0.31 (diluted) |
| Q2 FY2026 | $308M | $32M | $0.18 (diluted) |
| Q1 FY2026 | $268M | $4M | $0.02 (diluted) |
| Q4 FY2025 | $284M | $274M | $1.60 (diluted) |
What are the financial strengths and risks for Acadia Pharmaceuticals (ACAD)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway. The MoonshotScore pillars rate business quality, balance-sheet strength, durable growth as strengths. The distress and quality screens read Altman Z 4.88 · Piotroski F 4. Trailing ratios: ROE 28.0% · ROA 20.2% · current ratio 3.82 · earnings yield 9.9% · free-cash-flow yield 3.0%.
What should you watch next at Acadia Pharmaceuticals (ACAD)?
Short answer · as of
Current published price targets run low $14.50 · high $38.00 · consensus $30.05 · median $33.00 against a quoted price of $17.83 (as of Nov 18, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Acadia Pharmaceuticals compare with its peers?
Short answer
Acadia Pharmaceuticals's score ranks 7th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.56 Nov 18, 2026 | $3.01B | 97 5-pillar Nov 18, 2026 | |
| $58.26 Nov 19, 2026 | $2.97B | 95 5-pillar Nov 18, 2026 | |
| $27.61 Nov 18, 2026 | $3.49B | 89 5-pillar Nov 18, 2026 | |
| $25.57 Nov 18, 2026 | $2.06B | 89 5-pillar Nov 18, 2026 | |
| $41.37 Nov 18, 2026 | $4.53B | 84 5-pillar Nov 18, 2026 | |
| $44.89 Nov 18, 2026 | $3.30B | 72 5-pillar Nov 18, 2026 | |
| Acadia Pharmaceuticals (ACAD) — this page | $17.83 | $3.08B | 68 |
| $26.62 Nov 18, 2026 | $3.42B | 66 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 | |
| $17.95 Nov 18, 2026 | $3.66B | 63 5-pillar Nov 18, 2026 | |
| $21.89 Nov 18, 2026 | $3.71B | 62 5-pillar Nov 18, 2026 | |
| $53.42 Nov 18, 2026 | $2.65B | 61 5-pillar Nov 18, 2026 | |
| $305.19 Nov 18, 2026 | $8.53B | 60 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $14.50 – $38.00
- Consensus target
- $30.05
- Median target
- $33.00
Consensus record · Captured .
Measured against a quoted price of $17.83 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 30, 2026
- Transactions
- 42
- Identified insiders
- 10
- Purchases
- 0
- Sales
- 8
- Other transactions
- 34
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ACAD in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ACAD in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Acadia Pharmaceuticals (ACAD)?
- ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
- Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results for Remlifanserin
- Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Acadia Pharmaceuticals Healthcare Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ACAD research dossier (written May 10, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ACAD?
ACAD carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ACAD a good stock to buy?
Stock Expert AI does not rate ACAD buy, sell or hold. Acadia Pharmaceuticals Inc. carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ACAD stock price today?
The last price recorded for Acadia Pharmaceuticals Inc. (ACAD), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ACAD price target?
The analyst consensus price target for Acadia Pharmaceuticals Inc. (ACAD), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
How does ACADIA Pharmaceuticals Inc. navigate regulatory approval processes?
ACADIA Pharmaceuticals Inc. has a solid track record in navigating regulatory approval processes, having successfully launched NUPLAZID. The company employs a dedicated regulatory affairs team to ensure compliance with FDA and EMA guidelines.
What are the key factors to evaluate for ACAD?
Acadia Pharmaceuticals Inc. (ACAD) holds a MoonshotScore in the moderate range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Successful results could lead to FDA approval, expanding ACADIA's market presence and revenue potential. Not financial advice.
How frequently does ACAD data refresh on this page?
ACAD's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ACAD's recent stock price performance?
Acadia Pharmaceuticals Inc. (ACAD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong pipeline with multiple candidates in advanced clinical stages. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACAD overvalued or undervalued right now?
The trailing P/E of Acadia Pharmaceuticals Inc. (ACAD) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 30 figures on this page — 1 from SEC filings and earnings calls, 24 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
ETFs that hold ACAD
Funds in our ETF coverage that list ACAD among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| iShares Neuroscience and Healthcare ETF (IBRN) | 3.70% |